Comparative proteomic analysis of GS-NS0 murine myeloma cell lines with varying recombinant monoclonal antibody production rate. 2004

C M Smales, and D M Dinnis, and S H Stansfield, and D Alete, and E A Sage, and J R Birch, and A J Racher, and C T Marshall, and D C James
Research School of Biosciences, University of Kent, Canterbury, Kent, CT2 7NJ, United Kingdom.

We have employed an inverse engineering strategy based on quantitative proteome analysis to identify changes in intracellular protein abundance that correlate with increased specific recombinant monoclonal antibody production (qMab) by engineered murine myeloma (NS0) cells. Four homogeneous NS0 cell lines differing in qMab were isolated from a pool of primary transfectants. The proteome of each stably transfected cell line was analyzed at mid-exponential growth phase by two-dimensional gel electrophoresis (2D-PAGE) and individual protein spot volume data derived from digitized gel images were compared statistically. To identify changes in protein abundance associated with qMab datasets were screened for proteins that exhibited either a linear correlation with cell line qMab or a conserved change in abundance specific only to the cell line with highest qMab. Several proteins with altered abundance were identified by mass spectrometry. Proteins exhibiting a significant increase in abundance with increasing qMab included molecular chaperones known to interact directly with nascent immunoglobulins during their folding and assembly (e.g., BiP, endoplasmin, protein disulfide isomerase). 2D-PAGE analysis showed that in all cell lines Mab light chain was more abundant than heavy chain, indicating that this is a likely prerequisite for efficient Mab production. In summary, these data reveal both the adaptive responses and molecular mechanisms enabling mammalian cells in culture to achieve high-level recombinant monoclonal antibody production.

UI MeSH Term Description Entries
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D000222 Adaptation, Physiological The non-genetic biological changes of an organism in response to challenges in its ENVIRONMENT. Adaptation, Physiologic,Adaptations, Physiologic,Adaptations, Physiological,Adaptive Plasticity,Phenotypic Plasticity,Physiological Adaptation,Physiologic Adaptation,Physiologic Adaptations,Physiological Adaptations,Plasticity, Adaptive,Plasticity, Phenotypic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D015972 Gene Expression Regulation, Neoplastic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue. Neoplastic Gene Expression Regulation,Regulation of Gene Expression, Neoplastic,Regulation, Gene Expression, Neoplastic
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D020543 Proteome The protein complement of an organism coded for by its genome. Proteomes

Related Publications

C M Smales, and D M Dinnis, and S H Stansfield, and D Alete, and E A Sage, and J R Birch, and A J Racher, and C T Marshall, and D C James
December 2005, Proteomics,
C M Smales, and D M Dinnis, and S H Stansfield, and D Alete, and E A Sage, and J R Birch, and A J Racher, and C T Marshall, and D C James
September 1997, Biotechnology and bioengineering,
C M Smales, and D M Dinnis, and S H Stansfield, and D Alete, and E A Sage, and J R Birch, and A J Racher, and C T Marshall, and D C James
October 2001, Biotechnology and bioengineering,
C M Smales, and D M Dinnis, and S H Stansfield, and D Alete, and E A Sage, and J R Birch, and A J Racher, and C T Marshall, and D C James
June 2007, Biotechnology and bioengineering,
C M Smales, and D M Dinnis, and S H Stansfield, and D Alete, and E A Sage, and J R Birch, and A J Racher, and C T Marshall, and D C James
February 2012, Hybridoma (2005),
C M Smales, and D M Dinnis, and S H Stansfield, and D Alete, and E A Sage, and J R Birch, and A J Racher, and C T Marshall, and D C James
February 2007, Biotechnology and bioengineering,
C M Smales, and D M Dinnis, and S H Stansfield, and D Alete, and E A Sage, and J R Birch, and A J Racher, and C T Marshall, and D C James
February 2007, Biotechnology and bioengineering,
C M Smales, and D M Dinnis, and S H Stansfield, and D Alete, and E A Sage, and J R Birch, and A J Racher, and C T Marshall, and D C James
February 2000, Cytotechnology,
C M Smales, and D M Dinnis, and S H Stansfield, and D Alete, and E A Sage, and J R Birch, and A J Racher, and C T Marshall, and D C James
September 2000, Biotechnology and bioengineering,
C M Smales, and D M Dinnis, and S H Stansfield, and D Alete, and E A Sage, and J R Birch, and A J Racher, and C T Marshall, and D C James
July 2009, Sheng wu gong cheng xue bao = Chinese journal of biotechnology,
Copied contents to your clipboard!